Remove 2022 Remove Competition Remove Physicians
article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

But increased competition is on the horizon. Both the physician and the patient have to be registered and the drugs can only come from a primary source through limited distribution. Competition starts to heat up. The post Competition is on the horizon for costly narcolepsy treatments appeared first on. About the author.

article thumbnail

ESMO 2022: shrinking market for Trodelvy, with fierce ADC competition

Pharmaceutical Technology

A global Phase III TROPiCS-02 study evaluated the use of Trodelvy in comparison to physicians’ choice of chemotherapy in 543 HR+/HER2- metastatic breast cancer patients who were previously treated with endocrine therapy, CDK 4/6 inhibitors and at least two lines of chemotherapy. months) versus physicians’ choice chemotherapy (11.2

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How provider organizations can use data analytics to increase physician engagement

Clarify Health

Physician engagement is a crucial factor in the success and growth of healthcare organizations. Engaged physicians are not only more likely to deliver high-quality care to patients, but also play a pivotal role in driving operational efficiency and innovation. Areas to focus on include: Patient outcomes.

article thumbnail

The AMJEVITA impact: Innovative U.S. biosimilar pricing models

Clarivate

The Biosimilars Forum has hailed 2022 as a watershed year that could create a more competitive U.S. In 2022, it made its manufacturer, AbbVie, $21.2bn. Clarivate research indicates biosimilar competition will drive down prices and relative market share of HUMIRA ® in the U.S. from 91% in 2023 to 36% by 2031.

article thumbnail

9 Healthcare Marketing Trends to Embrace in 2023

Healthcare Success

In this blog, I share nine healthcare marketing trends you need to embrace in 2023 to remain competitive in today’s ever-changing healthcare marketplace. Competition from Retail and Telehealth Disruptors Continues to Intensif y. The COVID-19 pandemic supercharged a new type of competition for legacy healthcare organizations.

article thumbnail

Proposed Changes to Remote Therapeutic Monitoring Reimbursement in the Proposed 2023 Medicare Physician Fee Schedule

Nixon Gwilt Law

Every summer when the Centers for Medicare and Medicaid Services (“CMS”) releases the Medicare Physician Fee Schedule Proposed Rule (the “Proposed Rule”), the Nixon Gwilt Law (“NGL”) team excitedly opens the two-thousand-something-page PDF and immediately keys “ctrl+F” (or command+F for us Mac users) to jump to our most anticipated section(s).

article thumbnail

Consequences of the First 10 Drugs Selected for Medicare’s Negotiation Program

PM360

They do not have biosimilar or generic competition available in the market. They represent the top 10 eligible products based on highest gross Medicare spending between June 2022 and May 2023. Additionally, highly competitive classes, such as rapid-acting insulin and immunologics are included on the selected drug list.